David First - 10 Feb 2022 Form 4 Insider Report for SQZ Biotechnologies Co

Role
Chief People Officer
Signature
/s/ Lawrence Knopf, Attorney-in-Fact for David First
Issuer symbol
N/A
Transactions as of
10 Feb 2022
Net transactions value
$0
Form type
4
Filing time
15 Feb 2022, 16:15:48 UTC
Next filing
26 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SQZB Stock Option Award $0 +66,000 $0.000000 66,000 10 Feb 2022 Common Stock 66,000 $6.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying securities on February 10, 2023 and in 36 substantially equal monthly installments thereafter.